INMB Q2 2023 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46,000+187.5% YoY

Gross Profit

$46,000100.0% margin

Operating Income

-$6M-13937.0% margin

Net Income

-$7M-14132.6% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+21.1%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$70M

Total Liabilities

$19M

Stockholders' Equity

$51M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46,000	$16,000	+187.5%
Gross Profit	$46,000	$16,000	+187.5%
Operating Income	-$6M	-$6M	-0.4%
Net Income	-$7M	-$7M	+4.9%